Stent thrombosis with second-versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: Analysis of 3806 consecutive procedures from a large-volume single-center prospective registry

Journal of Invasive Cardiology

Volumn 25, Issue 7, 2013, Pages 330-336

  Dores, Helder ^a   Raposo, Luís ^a   Campante Teles, Rui ^a   MacHado, Carina ^a   Leal, Sílvio ^a   Araújo Gonçalves, Pedro ^a   Mesquita Gabriel, Henrique ^a   Sousa Almeida, Manuel ^a   Mendes, Miguel ^a  

^a Santa Cruz Hospital   (Portugal)

Author keywords

drug eluting stent; stent thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREVALENCE; REVASCULARIZATION; RISK FACTOR; STENT THROMBOSIS;

EID: 84886603314     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56(17):1357-1365.
2. Van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53(16):1399-1409.
3. Sarn G, Lagerqvist B, Frobert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606-613.
4. Planer D, Smits PC, Kereiakes DJ, et al. Comparison of everolimus and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials. JACC Cardiovasc Interv. 2011;4(10):1104-1115.
5. Cassese S, Piccolo R, Galasso G, et al. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel-And sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-Analysis of randomized clinical trials. Int J Cardiol. 2011;150(1):84-89.
6. de Waha A, Cassese S, Park DW, et al. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-Analysis of randomized trials. Clin Res Cardiol. 2012;101(6):461-467.
7. Stone GW, Newman W, Mastali K, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663-1674.
8. Cutlip D, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
9. Kamenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-coronary stent implantation: randomized, multicenter, open-label, controlled trial. Lancet. 2012;380(9851):1396-1405.
10. Kolandaivelu K, Swaminathan R, Gibson W, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123(13):1400-1409.
11. Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol. 2009;53(8):658-664.
12. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678.
13. Torre-Hernandez J, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51(10):986-990.
14. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention. 2006;2(3):286-294.
15. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119(5):680-686.
16. Stone GW. SPIRIT IV. Late breaking clinical trial. Presented at Transcatheter Cardiovascular Therapeutics, San Francisco, California, September 23, 2009.
17. Smits P. COMPARE trial. Presented at Transcatheter Cardiovascular Therapeutics, San Francisco, California, September 23, 2009.
18. Leon M. The ENDEAVOR and ENDEAVOR Resolute zotarolimus-eluting stent: comprehensive update of the clinical trial program (featuring the first presentation of the ENDEAVOR IV 3-year results). Paper presented at Transcatheter Cardiovascular Therapeutics, San Francisco, California, September 21, 2009.
19. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus and paclitaxel-eluting stents for coronary revascularization. The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) randomized trial. Am Coll Cardiol. 2010;56(15):1187-1195.
20. Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012;125(10):1246-1255.
21. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus and paclitaxel-eluting stents for coronary revascularization. The ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol. 2010;56(15):1187-1195.
22. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomized controlled superiority trial. Lancet. 2010;375(9720):1090-1099.
23. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
24. Raber L. SIRTAX-LATE: five-year clinical and angiographic follow-up from a prospective randomized trial of sirolimus-eluting and paclitaxel-eluting stents. Presented at Transcatheter Cardiovascular Therapeutics, San Francisco, California, September 22, 2009.
25. Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation. 2011;123(24):2819-2828.
26. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-Analysis. Lancet. 2012;379(9824):1393-1402.
27. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans. J Am Coll Cardiol. 2006;48(1):193-202.
28. Cayla G, Hulot JA, O'Connor S, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765-1774.
29. Chitkara K, Gershlick A. Second versus first-generation drug-eluting stents. J Interv Cardiol. 2010;5:23-26.
30. Morice MC, Serruys PW, Eduardo SJ, et al; the RAVEL study group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-1780.
31. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323.